Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 18/20 | 0.47 |
| ▸ | MTOR | P42345 | 2/20 | 0.43 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1984784 | 0.85 | PIK3CA (0.58) | PIK3CAMTOR | |
| SCHEMBL8214200 | 0.83 | PIK3CA (0.47) | PIK3CAMTOR | |
| SCHEMBL13439636 | 0.83 | PIK3CA (0.43) | PIK3CAMTOR | |
| SCHEMBL1983467 | 0.83 | PIK3CA (0.58) | PIK3CAMTOR | |
| SCHEMBL27361395 | 0.79 | CDK2 (0.55) | CCNT1CDK9 | |
| SCHEMBL1984858 | 0.79 | PIK3CA (0.51) | PIK3CAMTOR | |
| SCHEMBL5900336 | 0.79 | PIK3CA (0.48) | PIK3CAMTOR | |
| SCHEMBL4220929 | 0.79 | MEN1 (0.41) | PIK3CAMTORCCNT1CDK9 | |
| SCHEMBL5115244 | 0.78 | MEN1 (0.43) | PIK3CACCNT1CDK9 | |
| SCHEMBL1986399 | 0.77 | MTOR (0.75) | PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255162-A1 | Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents | WARNER-LAMBERT COMPANY LLC | 2008-10-16 | — | — | US | disclosed |
| EP-1749004-B1 | PYRROLYL SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7-ONES AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS | WARNER LAMBERT CO (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1749004-A1 | PYRROLYL SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7-ONES AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS | Warner-Lambert Company LLC (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005105801-A1 | PYRROLYL SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7-ONES AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255162-A1 | Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents | TYMS, DPYD, TYMP | PIK3CA 209/4885MTOR 1530/4885CCNT1 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.